Blanket Purchase Agreement 36F79718D0403-36E79725A0010
Award Date
5/22/25
Last Date to Order
5/21/26
Federal Agency
National Acquisition Center
Awardee
Daiichi Sankyo, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The U.S. Department of Veterans Affairs (VA) awarded Daiichi Sankyo, Inc. a single-award Blanket Purchase Agreement (BPA) under the GSA Pharmaceuticals and Drugs Schedule. The BPA has a ceiling value of $1,378,620 and a period of performance from May 22, 2020 to May 21, 2025. The purpose of this contract is to provide the VA healthcare system with a stable supply of the specialty pharmaceutical product pexidartinib, marketed under the brand name TURALIO, for the treatment of tenosynovial giant...
The Department of Veterans Affairs (VA) awarded Daiichi Sankyo, Inc., a for-profit pharmaceutical manufacturer, a Federal Supply Schedule (FSS) contract to supply the drug pexidartinib (marketed as TURALIO) to VA healthcare facilities. The $411.9 million IDV contract, awarded under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB), has an ultimate completion date of October 1, 2025. The VA has placed multiple firm fixed-price delivery orders against this IDV, ranging from $7,593 to...
This Blanket Purchase Agreement (BPA) is a single-award indefinite delivery vehicle (IDV) held by Takeda Pharmaceuticals America, Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited. The BPA, valued at $123.5 million, was awarded by the Department of Veterans Affairs (VA) National Acquisition Center and is set to run through October 2025. The primary purpose of this BPA is to provide the VA with a streamlined procurement mechanism for the specialty...
The U.S. Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical products, under the company's General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs. The single-award BPA, valued at over $13 million, is for the supply of the oncology medication ICLUSIG (ponatinib) to various VA Medical Centers and Veterans Integrated Service Networks (VISNs)...
The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Takeda Pharmaceuticals America Inc. in July 2020. The $19,472,334.90 BPA, which falls under Takeda's General Services Administration (GSA) Pharmaceutical and Drugs Schedule contract, facilitates the streamlined procurement of critical specialty pharmaceutical products for the VA healthcare system. Key products under this BPA include CINRYZE and KALBITOR for...
Takeda Pharmaceuticals America, Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, holds a $123.5 million Blanket Purchase Agreement (BPA) with the U.S. Department of Veterans Affairs (VA) National Acquisition Center. This single-award, indefinite delivery vehicle under GSA Schedule 61-IB for Pharmaceuticals and Drugs enables the VA to efficiently procure the specialty oncology medication ICLUSIG (ponatinib) for distribution to VA medical facilities...
The Blanket Purchase Agreement was awarded as a single-award contract by the Department of Veterans Affairs National Acquisition Center on April 14, 2022. The agreement is with Calliditas Therapeutics US Inc. to provide TARPEYO for a potential value of $1,750,000.00. TARPEYO is a treatment for the uncontrolled proteinuria in adult patients with primary immunoglobulin A nephropathy. As a single-award BPA with no set-aside, Calliditas Therapeutics will serve as the sole provider of this...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to United Therapeutics Corporation, a self-certified small disadvantaged business and for-profit manufacturer of pharmaceutical goods. The BPA has a ceiling value of $207,127,385 and a performance period extending through April 2026. It allows the VA to procure specialized pharmaceutical products from United Therapeutics' portfolio, including Orenitram, Remodulin, Tyvaso,...
This Blanket Purchase Agreement (BPA) contract was awarded by the National Acquisition Center, a civilian agency, to Otsuka America Pharmaceutical Inc., a large pharmaceutical manufacturer. The $83,342,090.00 BPA is for the supply of the drug Jynarque (tolvaptan) to the Department of Veterans Affairs (VA) healthcare system. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The BPA was awarded under the Pharmaceuticals and Drugs Federal Supply Schedule...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Amryt Pharmaceuticals Inc., a foreign-owned, for-profit organization, on November 5, 2022. The potential value of the BPA is $1,000,000. No set-aside was used. The BPA is for a single award and permits ordering of Mycapssa, Juxtapid, and Myalept through March 14, 2024. Mycapssa, Juxtapid, and Myalept are pharmaceutical products used to treat certain rare diseases. The Department of...